Sunday, July 6, 2025
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Fiinews
No Result
View All Result
Home Exports

US FDA accept clinical studies on acne product

Fiinews by Fiinews
January 7, 2016
in Exports, Health
Reading Time: 2 mins read
A A
0
0
SHARES
10
VIEWS
LinkedinShare on Twitter

0:00

Ventak2
Venkat says Vyome has become a clinical company in US.
The US Food and Drug Administration (US FDA) has accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne.
The New Delhi-based Vyome plans to start the Phase I clinical trials very soon.
According to the American Academy of Dermatology, acne represents the most common skin disease, affecting 85% of teenagers and affects 40-50 million people in the US.
Approximately 40% of acne patients are suffering from antibiotic resistance.
Physicians around the world have cited a large unmet need for new, improved topical therapy options, vis-à-vis the current available topical products.
Vyome’s program VB 1953 targets this large unmet need of an effective topical treatment option.
“With the US FDA accepting our first IND application for the lead program VB 1953, we have become a clinical stage company in the USA, which is an important value inflection milestone for us. This should pave the way for further filings with the US FDA in the future. VB 1953 is a first-in-class new product in acne therapy for addressing one of the very important and large unmet needs,” remarked N. Venkat, Co-Founder & CEO at Vyome.
“Successful IND acceptance of VB 1953 by the US FDA, is a culmination of tremendous efforts by Vyome’s product discovery & development team. I am extremely delighted at Vyome’s significant achievement and look forward to more of them in the future,” said Dr. Raghunath Mashelkar, Chairman of Vyome’s Board of Directors.
Apart from the lead program VB 1953, Vyome has a deep R&D pipeline of Dual Action Rational Therapeutics (DARTs) antibiotics that are very less prone to resistance development. Vyome also has a portfolio of clinically tested and commercialized products with superior efficacy for various fungal indications, developed using its breakthrough technology platform Molecular Replacement Therapy (MRTTM).
Vyome Biosciences is a clinical-stage, dermatology-based biopharmaceutical company, which has novel platform technologies and a deep pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents.
Vyome has put together a team of scientific and management experts from India and USA to deliver the company’s growth plans. Vyome is co-promoted by Shiladitya Sengupta, N. Venkat, Rajesh Gokhale and Rajeev Mantri. fii-news.com
ShareTweetShare

Related Posts

SOPA
Exports

Export: India to ship non-GMO soybean to EU

by Fiinews
July 6, 2025
0
16

Global demand for deforestation-free non-GMO soy rises Indian non-GMO soy is a natural fit for EU buyers seeking sustainable and...

Toy Biz International2
Exports

Export: India supplies toys to 153 countries

by Fiinews
July 6, 2025
0
19

Minister tells industry to focus on good branding Toys manufactured in India are exported to 153 countries, Commerce and Industry...

Ministry of Textile

Export: Govt to facilitate easy trade environment

July 2, 2025
15
Aieclogo

Export: Focus on competiing in global markets

June 27, 2025
13
Credlix Logo

Export: Credlix launches India-Mexico service

June 25, 2025
13
World Steel

Export: New rules imposed on material imports

June 23, 2025
15
SBI YONO

POPULAR NEWS

  • Cristina Dnv

    Projects: Indian yards set to build green ships, says DNV expert

    0 shares
    Share 0 Tweet 0
  • Market: Indian-origin UGF scales heritage consumer brands globally

    0 shares
    Share 0 Tweet 0
  • Technologies: Royal Diamond sponsors aerspace Industries’ drones in UAE

    0 shares
    Share 0 Tweet 0
  • Investments: Foreign investors see India as long-term destination for fund placings

    0 shares
    Share 0 Tweet 0
  • Markets: Blue Dart maintains positive outlook on India

    0 shares
    Share 0 Tweet 0

Fiinews.com features through news articles on business opportunities in the Indian market for the benefits of foreigners. It is also a platform for international businesses to showcase through elaborate articles on their products & services to the Indian consumers and corporations exploiting industrialisation of the country.

7Clicks Media is a Singapore based Media & PR company offering over 100,000
impressions via our targeted communication strategy.

It is led by editor-in-chief Gurdip Singh who has worked over 45 years reporting on
Asian businesses.

Recent News

  • Export: India to ship non-GMO soybean to EU
  • Tender: Take care of new urban development
  • Manufacturing: Framework on Drones by Sep-Oct
  • Project: Joint maritime professionals launched
  • Market: Daimler bullish on construction sector

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY

Subscribe to Newsletter

  • About
  • Advertise
  • Careers
  • Contact us

© 2024 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports

© 2024 FIINEWS - Design and developed by 7clicksmedia.